Literature DB >> 8519047

Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group.

L Parnetti1, U Senin, M Carosi, H Baasch.   

Abstract

The efficacy and tolerability of nimodipine, a calcium antagonist selective for the central nervous system, was evaluated in old age dementias in two multicenter, clinical trials. A total of 755 elderly patients suffering from mental deterioration of degenerative or vascular origin were enrolled in the studies. In the first study, 352 patients received nimodipine 30 mg TID orally for 3 months; in the second study, 403 patients received the same treatment for 6 months. In both studies, psychobehavioral instruments showed a highly significant improvement of the global functional state. In hypertensive patients, nimodipine had a synergistic effect with the antihypertensive drugs. These results confirm the therapeutic efficacy and safety of nimodipine in the treatment of old age dementias.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8519047

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  5 in total

1.  N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports.

Authors:  E Wiebe
Journal:  Can Fam Physician       Date:  1996-11       Impact factor: 3.275

2.  Reversal of age-related alterations in synaptic plasticity by blockade of L-type Ca2+ channels.

Authors:  C M Norris; S Halpain; T C Foster
Journal:  J Neurosci       Date:  1998-05-01       Impact factor: 6.167

Review 3.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 4.  Calcium channel blockers and dementia.

Authors:  V Nimmrich; A Eckert
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 5.  Nimodipine Reappraised: An Old Drug With a Future.

Authors:  Andrew P Carlson; Daniel Hänggi; Robert L Macdonald; Claude W Shuttleworth
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.